Author:
Zhao Guo-zhen,Yan Shi-yan,Li Bo,Guo Yu-hong,Song Shuang,Hu Ya-hui,Guo Shi-qi,Hu Jing,Du Yuan,Lu Hai-tian,Ye Hao-ran,Ren Zhi-ying,Zhu Ling-fei,Xu Xiao-long,Su Rui,Liu Qing-quan
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. World Health Organization. Therapeutics and COVID-19: living guideline; 2022. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4. Accessed April 23, 2023.
2. World Health Organization. WHO coronavirus disease (COVID-19) dashboard; 2019. Available at: https://covid19.who.int/. Accessed April 23, 2023.
3. Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. BMJ 2020;370:m3379.
4. General Office of the National Health and Health Commission, Office of the State Administration of Traditional Chinese Medicine. Notice on issuing a new coronary virus pneumonia diagnosis and treatment guidelines (Trial version 9); 2022. Available at: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml. Accessed April 23, 2023.
5. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 2022;386:1397–1408.